Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients

O.S. Ademowo, H.K.I. Dias, I. Milic, A. Devitt, R. Moran, R. Mulcahy, A.N. Howard, J.M. Nolan, H.R. Griffiths

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease (AD) is a progressive, neurodegenerative disease, characterised by decline of memory, cognitive function and changes in behaviour. Generic markers of lipid peroxidation are increased in AD, therefore reactive oxygen species have been suggested to be involved in the aetiology of cognitive decline. Carotenoids are depleted in AD serum, therefore we have compared serum lipid oxidation between AD and age-matched control subjects before and after carotenoid supplementation. The novel oxidised phospholipid biomarker 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) was analysed using electrospray ionization tandem mass spectrometry (MS) with multiple reaction monitoring (MRM), 8-isoprostane (IsoP) was measured by ELISA and ferric reducing antioxidant potential (FRAP) was measured by a colorimetric assay.
AD patients (n=21) and healthy age-matched control subjects (n=16) were supplemented with either Macushield™ (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or placebo (sunflower oil) for six months.
The MRM-MS method determined serum POVPC sensitively (from 10 µl serum) and reproducibly (CV=7.9%). At baseline, AD subjects had higher serum POVPC compared to age-matched controls, (p=0.017) and cognitive function was correlated inversely with POVPC (r=−0.37; p=0.04). After six months of carotenoid intervention, serum POVPC was not different in AD patients compared to healthy controls. However, POVPC was significantly higher in control subjects after six months of carotenoid intervention compared to their baseline (p=0.03). Serum IsoP concentration was unrelated to disease or supplementation. Serum FRAP was significantly lower in AD than healthy controls but was unchanged by carotenoid intervention (p=0.003).
In conclusion, serum POVPC is higher in AD patients compared to control subjects, is not reduced by carotenoid supplementation and correlates with cognitive function.
LanguageEnglish
Pages77-85
Number of pages9
JournalFree Radical Biology and Medicine
Volume108
Early online date14 Mar 2017
DOIs
Publication statusPublished - Jul 2017

Fingerprint

Carotenoids
Phospholipids
Alzheimer Disease
Oxidation
8-epi-prostaglandin F2alpha
Serum
Cognition
Mass spectrometry
Antioxidants
Lutein
Neurodegenerative diseases
Lipids
Phosphorylcholine
Electrospray Ionization Mass Spectrometry
Electrospray ionization
Monitoring
Tandem Mass Spectrometry
Biomarkers
Neurodegenerative Diseases
Lipid Peroxidation

Bibliographical note

© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Funding: BBSRC; Kidney Research Foundation; ARUK; Howard Foundation; and Aston Research Centre for Healthy Ageing

Keywords

  • oxidative stress
  • lipid peroxidation
  • POVPC
  • mass spectrometry
  • lutein
  • meso-zeaxanthin
  • zeaxanthin
  • cognitive function
  • supplementation

Cite this

Ademowo, O.S. ; Dias, H.K.I. ; Milic, I. ; Devitt, A. ; Moran, R. ; Mulcahy, R. ; Howard, A.N. ; Nolan, J.M. ; Griffiths, H.R. / Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients. In: Free Radical Biology and Medicine. 2017 ; Vol. 108. pp. 77-85.
@article{519209afe53342bf84933f7ce4d9ddc0,
title = "Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients",
abstract = "Alzheimer's disease (AD) is a progressive, neurodegenerative disease, characterised by decline of memory, cognitive function and changes in behaviour. Generic markers of lipid peroxidation are increased in AD, therefore reactive oxygen species have been suggested to be involved in the aetiology of cognitive decline. Carotenoids are depleted in AD serum, therefore we have compared serum lipid oxidation between AD and age-matched control subjects before and after carotenoid supplementation. The novel oxidised phospholipid biomarker 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) was analysed using electrospray ionization tandem mass spectrometry (MS) with multiple reaction monitoring (MRM), 8-isoprostane (IsoP) was measured by ELISA and ferric reducing antioxidant potential (FRAP) was measured by a colorimetric assay. AD patients (n=21) and healthy age-matched control subjects (n=16) were supplemented with either Macushield™ (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or placebo (sunflower oil) for six months. The MRM-MS method determined serum POVPC sensitively (from 10 µl serum) and reproducibly (CV=7.9{\%}). At baseline, AD subjects had higher serum POVPC compared to age-matched controls, (p=0.017) and cognitive function was correlated inversely with POVPC (r=−0.37; p=0.04). After six months of carotenoid intervention, serum POVPC was not different in AD patients compared to healthy controls. However, POVPC was significantly higher in control subjects after six months of carotenoid intervention compared to their baseline (p=0.03). Serum IsoP concentration was unrelated to disease or supplementation. Serum FRAP was significantly lower in AD than healthy controls but was unchanged by carotenoid intervention (p=0.003). In conclusion, serum POVPC is higher in AD patients compared to control subjects, is not reduced by carotenoid supplementation and correlates with cognitive function.",
keywords = "oxidative stress, lipid peroxidation, POVPC, mass spectrometry, lutein, meso-zeaxanthin, zeaxanthin, cognitive function, supplementation",
author = "O.S. Ademowo and H.K.I. Dias and I. Milic and A. Devitt and R. Moran and R. Mulcahy and A.N. Howard and J.M. Nolan and H.R. Griffiths",
note = "{\circledC} 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Funding: BBSRC; Kidney Research Foundation; ARUK; Howard Foundation; and Aston Research Centre for Healthy Ageing",
year = "2017",
month = "7",
doi = "10.1016/j.freeradbiomed.2017.03.008",
language = "English",
volume = "108",
pages = "77--85",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier",

}

Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients. / Ademowo, O.S.; Dias, H.K.I.; Milic, I.; Devitt, A.; Moran, R.; Mulcahy, R.; Howard, A.N.; Nolan, J.M.; Griffiths, H.R.

In: Free Radical Biology and Medicine, Vol. 108, 07.2017, p. 77-85.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients

AU - Ademowo, O.S.

AU - Dias, H.K.I.

AU - Milic, I.

AU - Devitt, A.

AU - Moran, R.

AU - Mulcahy, R.

AU - Howard, A.N.

AU - Nolan, J.M.

AU - Griffiths, H.R.

N1 - © 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Funding: BBSRC; Kidney Research Foundation; ARUK; Howard Foundation; and Aston Research Centre for Healthy Ageing

PY - 2017/7

Y1 - 2017/7

N2 - Alzheimer's disease (AD) is a progressive, neurodegenerative disease, characterised by decline of memory, cognitive function and changes in behaviour. Generic markers of lipid peroxidation are increased in AD, therefore reactive oxygen species have been suggested to be involved in the aetiology of cognitive decline. Carotenoids are depleted in AD serum, therefore we have compared serum lipid oxidation between AD and age-matched control subjects before and after carotenoid supplementation. The novel oxidised phospholipid biomarker 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) was analysed using electrospray ionization tandem mass spectrometry (MS) with multiple reaction monitoring (MRM), 8-isoprostane (IsoP) was measured by ELISA and ferric reducing antioxidant potential (FRAP) was measured by a colorimetric assay. AD patients (n=21) and healthy age-matched control subjects (n=16) were supplemented with either Macushield™ (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or placebo (sunflower oil) for six months. The MRM-MS method determined serum POVPC sensitively (from 10 µl serum) and reproducibly (CV=7.9%). At baseline, AD subjects had higher serum POVPC compared to age-matched controls, (p=0.017) and cognitive function was correlated inversely with POVPC (r=−0.37; p=0.04). After six months of carotenoid intervention, serum POVPC was not different in AD patients compared to healthy controls. However, POVPC was significantly higher in control subjects after six months of carotenoid intervention compared to their baseline (p=0.03). Serum IsoP concentration was unrelated to disease or supplementation. Serum FRAP was significantly lower in AD than healthy controls but was unchanged by carotenoid intervention (p=0.003). In conclusion, serum POVPC is higher in AD patients compared to control subjects, is not reduced by carotenoid supplementation and correlates with cognitive function.

AB - Alzheimer's disease (AD) is a progressive, neurodegenerative disease, characterised by decline of memory, cognitive function and changes in behaviour. Generic markers of lipid peroxidation are increased in AD, therefore reactive oxygen species have been suggested to be involved in the aetiology of cognitive decline. Carotenoids are depleted in AD serum, therefore we have compared serum lipid oxidation between AD and age-matched control subjects before and after carotenoid supplementation. The novel oxidised phospholipid biomarker 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) was analysed using electrospray ionization tandem mass spectrometry (MS) with multiple reaction monitoring (MRM), 8-isoprostane (IsoP) was measured by ELISA and ferric reducing antioxidant potential (FRAP) was measured by a colorimetric assay. AD patients (n=21) and healthy age-matched control subjects (n=16) were supplemented with either Macushield™ (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or placebo (sunflower oil) for six months. The MRM-MS method determined serum POVPC sensitively (from 10 µl serum) and reproducibly (CV=7.9%). At baseline, AD subjects had higher serum POVPC compared to age-matched controls, (p=0.017) and cognitive function was correlated inversely with POVPC (r=−0.37; p=0.04). After six months of carotenoid intervention, serum POVPC was not different in AD patients compared to healthy controls. However, POVPC was significantly higher in control subjects after six months of carotenoid intervention compared to their baseline (p=0.03). Serum IsoP concentration was unrelated to disease or supplementation. Serum FRAP was significantly lower in AD than healthy controls but was unchanged by carotenoid intervention (p=0.003). In conclusion, serum POVPC is higher in AD patients compared to control subjects, is not reduced by carotenoid supplementation and correlates with cognitive function.

KW - oxidative stress

KW - lipid peroxidation

KW - POVPC

KW - mass spectrometry

KW - lutein

KW - meso-zeaxanthin

KW - zeaxanthin

KW - cognitive function

KW - supplementation

UR - http://doi.org/10.17036/dd4fed57-df9e-439d-899e-59e242ec1a5f

UR - http://www.scopus.com/inward/record.url?scp=85015761126&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2017.03.008

DO - 10.1016/j.freeradbiomed.2017.03.008

M3 - Article

VL - 108

SP - 77

EP - 85

JO - Free Radical Biology and Medicine

T2 - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

ER -